Cardiology

PCSK9 inhibition with bococizumab yields mixed results

In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular ...

Oncology & Cancer

Prostate cancer and blood lipids share genetic links

Numerous studies have suggested a relationship between cardiovascular disease risk factors and prostate cancer. A new study by researchers at the University of California, San Diego School of Medicine, with colleagues in ...

Cardiology

Inclisiran lowers 'bad' cholesterol for up to 1 year

Inclisiran lowers low-density lipoprotein (LLD "bad" cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol, according to late-breaking results from the ORION 1 trial presented ...

Cardiology

Estimating cost when it comes to novel therapies

When it comes to patient care, finding the best treatment can sometimes include finding an equal, yet more economical solution. Rather than introducing a costly new medication, for some patients changing current dosages or ...

page 36 from 38